Merck’s Welireg-Lenvatinib Combination Wins EU Panel Backing for Advanced Kidney Cancer

Bitget2026/11/13 11:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Merck's Welireg with lenvatinib received a positive EU CHMP opinion for advanced clear cell kidney cancer following PD-1/PD-L1 inhibitor treatment.
A European Commission decision on marketing authorization is expected within two months.
The combination reduced disease progression or death risk by 26% versus cabozantinib; overall survival improvement was not statistically significant.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611130635BIZWIRE_USPR_____20261112_BW893799) on November 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Merck’s Welireg-Lenvatinib Combination Wins EU Panel Backing for Advanced Kidney Cancer

You may also like

Crypto prices